CLDX Earnings & Financial Statements
Celldex Therapeutics, Inc.
$28.44
+$0.61(+2.17%)
35
Overall
60
Value
18
Tech
28
Quality
Market Cap
$2.19B
Volume
295.42K
52W Range
$22.10 - $45.14
Target Price
$63.29
CLDX earnings and financial statements: Celldex Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
CLDX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.54M | $7.02M | $6.88M | $2.36M | $4.65M |
| Cost of revenue | - | - | - | $100.0K | $100.0K |
| Operating income | -$287.37M | -$195.08M | -$154.54M | -$115.23M | -$71.24M |
| EBITDA | -$255.08M | -$170.06M | -$152.11M | -$126.91M | -$66.08M |
| Net income | -$258.76M | -$157.86M | -$141.43M | -$112.33M | -$70.51M |
| EPS (diluted) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $582.98M | $792.34M | $465.63M | $352.74M | $444.65M |
| Total liabilities | $55.82M | $45.34M | $36.46M | $26.53M | $25.18M |
| Shareholders’ equity | $527.16M | $747.00M | $429.17M | $326.20M | $419.48M |
| Cash and equivalents | $28.87M | $28.36M | $34.81M | $29.43M | $39.14M |
| Long-term debt | $784.0K | $2.36M | $928.0K | $2.59M | $1.30M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$210.90M | -$157.78M | -$107.29M | -$103.73M | -$60.91M |
| Capital expenditure | -$2.71M | -$1.92M | -$1.82M | -$1.83M | -$1.25M |
| Free cash flow | -$213.61M | -$159.70M | -$109.11M | -$105.56M | -$62.16M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLDX | $28.44 | +2.2% | 295.42K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Celldex Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW